The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

  • LOG IN
  • BECOME A MEMBER
  • About
    • Mission & Activities
    • Directors and Officers
    • The Antibody Society’s Committees
      • Communication & Membership Committee
      • Meetings Committee
      • AIRR Community Working Groups & Subcommittees
    • Sponsors & Partners
  • Society meetings
    • Computational Antibody Discovery: State of the Art
      • Computational Antibody Discovery Symposium Participants
    • Harnessing Cytokines for Cancer Immunotherapy Symposium
    • Biopharmaceutical Informatics Symposium
    • Emerging Cancer Therapies Leveraging Gamma-Delta Effector T cells Symposium
    • Emerging Immunotherapeutics for Ovarian Cancer Symposium
    • AIRR Community Meetings
    • Antibody Engineering & Therapeutics (US) 2023
      • 2022 Antibody Engineering & Therapeutics
      • 2020 Antibody Engineering & Therapeutics
      • 2019 Antibody Engineering & Therapeutics
      • 2018 Antibody Engineering & Therapeutics
      • What is INN a Name?
        • INN issue updates
    • Antibody Engineering & Therapeutics Europe 2023
      • Scientific Advisors, Antibody Engineering & Therapeutics Europe
    • FOCIS Symposia
  • AIRR Community
    • AIRR News
    • AIRR Community Seminar Series
    • AIRR Publications
    • AIRR Meetings
      • AIRR Community Meeting VII – Learnings and Perspectives
      • AIRR Community Special Event 2023  – Zooming in to the Community II
      • AIRR Community Meeting VI: “Exploring New Frontiers”
      • AIRR Community Meeting V: “Zooming in to the AIRR Community”
      • AIRR Community Meeting V Pre-Meetings
        • AIRR-seq in the Pandemic
        • AIRR-seq Biological Standards and Workflows
      • AIRR Community Special Event: “Response to COVID-19”
      • AIRR Community Meeting IV: “Bridging the Gaps”
      • AIRR Community Meeting III
        • Day 1
        • Day 2
        • Day 3
        • Day 4
      • AIRR Community Meeting II
      • AIRR Community Meeting I
    • AIRR Community Working Groups
      • Biological Resources Working Group
      • Common Repository Working Group
      • Diagnostics Working Group
      • Germline Database Working Group
      • Legal and Ethics Working Group
      • Software Working Group
      • Standards Working Group
    • AIRR Community Sub-committees
      • Communications Sub-committee
      • Executive Sub-committee
      • Inferred Allele Review Committee
      • Meetings Sub-committee
      • Strategic Planning Sub-Committee
    • AIRR Data Commons
    • AIRR Community Calendar
    • AIRR Community Webinar Series
    • On AIRR – An AIRR Community Podcast
    • AIRR Community Resources
    • AIRR Community Service Prize 2022
  • Members only
    • Login
    • Note to members
    • Member discount codes
    • 2023 Calendar of Events
    • James S. Huston Antibody Science Talent Award
      • 2021 James S. Huston Antibody Science Talent Award Recipient
      • 2020 James S. Huston Antibody Science Talent Award Recipient
      • Huston Award Criteria
    • Science Writing Competition
      • Science Writing Competition Winners
    • Imaging Competition
      • Imaging Calendar Competition winners
    • Research Competitions
      • Research Competition Winners
    • Antibodies in early-stage studies
    • Presentations
  • Upcoming meetings
  • Web Resources
    • Society Publications
    • Antibody News
    • Antibody therapeutics approved or in regulatory review in the EU or US
      • Antibody therapeutics product data
    • Antibodies in late-stage clinical studies
    • Research Resources
    • Education Resources
  • Career Center
    • Career Shorts
  • Learning Center
    • Upcoming Webinars
    • Snakebite antivenoms: Global challenges and progress toward recombinant antibody therapeutics
    • Adaptive Immune Receptor Repertoires
    • Antibody Discovery & Development
    • Commercializing Antibody Therapeutics
    • Antibodies to Watch
    • Antibody Validation
  • COVID-19
    • Guide to “Coronavirus in the Crosshairs”
    • Meeting Report: The Diagnostic Landscape for COVID-19
You are here: Home / Learning Center / Upcoming Webinars

Upcoming Webinars

 



Registration is open!

Thursday October 26th at 11am ET/5pm CET

Versatility of Modular Antibodies: From Rapid Format Switch to Fast Screening of Libraries and Bispecifics

The SpyTag/SpyCatcher protein ligation technology is a versatile method to covalently link two proteins. Addition of the SpyTag protein ligation technology to antibodies creates a modular platform that offers a wide range of new opportunities. In this webinar Dr. Ylera will demonstrate the use of Spytagged antibodies in combination with prefabricated SpyCatcher modules for rapid site-specific labeling, as well as changing antibody valency, species and isotype. Furthermore, Dr. Ylera will present the use of SpyTag for antibody phage display selection (SpyDisplay) and for the generation of prototype bispecific antibodies. The work presented illustrates how these technologies work hand in hand for the generation of new therapeutic lead candidates.

Speaker: Francisco Ylera, PhD, Bio-Rad

Francisco Ylera is the head of the R&D team that generated the Pioneer Antibody Discovery Platform. He has been with Bio-Rad for over 18 years. Francisco has worked on customer antibody generation projects, and has been involved with designs selection, antibody characterization, and technical support, as well as method optimizations. Francisco holds a diploma in chemistry from RWTH Aachen University, Germany, and a Ph.D. in Biochemistry from the Free University Berlin, Germany. After his Ph.D., he did a postdoc at the Harvard Institute of Medicine, Boston, USA



Thursday November 9, 2023 11am ET/5pm CET

Registration is open!

​Strategies for Mitigating the Unpredictability of Fc-Mediated Functions ​in Antibody Development

Optimization of Fc function can lead to the development of safer and more efficacious therapeutic antibody products, but analyses of Fc function may be underexploited in the antibody design process. We introduce a high-throughput platform for antigen-specific testing of Fc effector activities, empowering enhanced hit-to-lead screening in early stages of antibody development for the treatment of cancer, autoimmunity, neurodegeneration, and infectious diseases.

Speaker: Lenny Moise, PhD, VP Research, SeromYx Systems

Dr. Lenny Moise, VP Research, oversees the scientific development of the SeromYx Systems Serology platform, driving clinical research and drug discovery in infectious disease, immuno-oncology, autoimmunity, and neurology. Previously, as Director of Vaccine Research at EpiVax, he harnessed immunoinformatics to design innovative vaccines leveraging T cell immunity for viral and bacterial infectious diseases and cancer. Over that time, he studied T cell responses to vaccines and developed immunoinformatic tools as a faculty member at the Institute for Immunology and Informatics (University of Rhode Island) and the Center for Vaccines and Immunology (University of Georgia). Lenny trained in structure-function analysis of snake toxin-ion channel interactions using structural, biochemical, and electrophysiological methods and holds a Bachelor of Science and a doctorate from Brown University.

 



Preview of other upcoming webinars:

  • November 7, 2023, Quality Control Pipelines for T cell and B cell AIRR-seq.
  •  January 2024, Presentation by Huston Antibody Science Talent Award winner
  •  January 2024, Antibodies to Watch in 2024



Note: The webinar platform and registration process is managed by Community Brands.
Their privacy policy is here.



Our selection of On Demand webinars can be viewed here.

Our YouTube channel includes selected webinars as well as recordings of our Symposia on topics such as:

  • Computational Antibody Discovery: State of the Art
  • Biopharmaceutical Informatics
  • Harnessing Cytokines for Cancer Immunotherapy
  • Emerging Immunotherapeutics for Ovarian Cancer Symposium
  • Emerging Cancer Therapies Leveraging Gamma-Delta Effector T cells

 


  • Home
  • Privacy & Terms of Use
  • About
  • Directors and Officers
  • Advisors
  • Sponsors & Partners
  • Mission & Activities
  • Join the Society
  • Membership Levels
  • Members only
  • Login
  • Antibody therapeutics approved or in regulatory review in the EU or US
  • Meeting reports
  • Presentations
  • Contact

©2015 - scicomvisuals